In this video, Barbara Blodi, MD, discusses early data on neuroprotective agents for the treatment of geographic atrophy.
In a phase 1b study presented during a dry AMD symposium at the ASRS meeting, the fatty acid synthase inhibitor ONL1204 (ONL Therapeutics) showed safety and tolerability.
In addition, Blodi discusses the phase 2/3 trial of AVD-104 (Aviceda Therapeutics) for geographic atrophy.